Bifogade filer
PDF
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Bio-Works Technologies AB has received an order worth SEK 5.5 million from a leading global pharmaceutical company, with delivery scheduled for Q4 2025. The order covers WorkBeads™ affimAb, a chromatography resin used for antibody purification in commercial manufacturing.
The customer, who has previously used WorkBeads affimAb in several commercial processes, has placed this repeat order as a strong sign of continued confidence in Bio-Works' products. The order reinforces the ongoing collaboration between the two companies and lays the foundation for a deeper long-term partnership.
WorkBeads affimAb is designed for efficient and selective purification of antibodies and is a highly attractive solution for industrial-scale biopharmaceutical production.
"Receiving a repeat order from a global pharmaceutical leader is a clear validation of our products' performance in demanding, large-scale processes. It confirms our strategy to be an innovative and trusted partner in biopharmaceutical manufacturing," says Lone Carlbom, CEO of Bio-Works Technologies AB.
This order reflects Bio-Works' continued growth and strengthens the company's position as a strategic supplier to the global biopharmaceutical industry.
This disclosure contains information that Bio-Works Technologies AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 11-07-2025 15:28 CET.